Search for content, post, videos

Aptamer Group extends collaboration with AstraZeneca

collaboration

This agreement will build upon the existing collaboration to evaluate the potential of using Optimer-based strategies to target renal cells and explore the feasibility of developing next-generation drug delivery vehicles, Optimer-drug conjugates.

Optimers are optimized aptamer reagents. Based on oligonucleotide molecules Optimers can bind specifically to a target molecule to act as an antibody alternative. Their ability to fold into distinct secondary or tertiary structures gives them high affinity and specific binding toward cell-specific targets, according to Aptamer. They are emerging as promising alternatives in a range of applications.

Optimer-based strategies

This extension will further unite Aptamer Group’s expertise and knowledge in the development of aptamer-based technologies with AstraZeneca’s leadership in Cardiovascular, Renal and Metabolism (CVRM) therapy development, the company states.

“Oligonucleotide conjugates offer the potential to reach a specific cell or tissue, and have the potential to have a real impact for new drug targets identified in renal disease. By working together with Aptamer Group and leveraging their Optimer-based strategies we aim to identify novel targeting aptamers to deliver drug molecules to the kidney,” says Regina Fritsche Danielson, Senior Vice President and Head of Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca.

Photo: iStock